Literature DB >> 17331066

Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease.

Ancha Baranova1, Manpreet Randhawa, Mohammed Jarrar, Zobair M Younossi.   

Abstract

Metabolic syndrome is associated with nonalcoholic fatty liver disease and its more aggressive form, nonalcoholic steatohepatitis. Adipokines produced by white adipose tissue possess broad physiological activity and play an important autocrine role in obesity-associated complications, including metabolic syndrome, nonalcoholic fatty liver disease and cardiovascular disease. Various adipokines may have beneficial or harmful effects. Other tissues, particularly stomach and intestine, produce active molecules that can influence the function of adipocytes and, possibly, the levels of adipokine secretion. In some cases, the production sites of these molecules remain unknown. The review focuses on our current understanding of the disease-related effects of the adipokines and the melanocortins on various peripheral tissues, and discusses some of their potential interactions with each other. Potential therapeutic applications are also considered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17331066     DOI: 10.1586/14737159.7.2.195

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  6 in total

1.  Adipose tissue proteomic analysis in ketotic or healthy Holstein cows in early lactation1.

Authors:  Qiushi Xu; Xiaobing Li; Li Ma; Juan J Loor; Danielle N Coleman; Hongdou Jia; Guowen Liu; Chuang Xu; Yazhe Wang; Xinwei Li
Journal:  J Anim Sci       Date:  2019-07-02       Impact factor: 3.159

2.  Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery.

Authors:  Marianna Argentou; Dina G Tiniakos; Menelaos Karanikolas; Maria Melachrinou; Maria G Makri; Christos Kittas; Fotis Kalfarentzos
Journal:  Obes Surg       Date:  2009-07-15       Impact factor: 4.129

3.  Knowledge-based identification of soluble biomarkers: hepatic fibrosis in NAFLD as an example.

Authors:  Sandra Page; Aybike Birerdinc; Michael Estep; Maria Stepanova; Arian Afendy; Emanuel Petricoin; Zobair Younossi; Vikas Chandhoke; Ancha Baranova
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

4.  Expression of inflammation-related genes is altered in gastric tissue of patients with advanced stages of NAFLD.

Authors:  Rohini Mehta; Aybike Birerdinc; Arpan Neupane; Amirhossein Shamsaddini; Arian Afendy; Hazem Elariny; Vikas Chandhoke; Ancha Baranova; Zobair M Younossi
Journal:  Mediators Inflamm       Date:  2013-03-30       Impact factor: 4.711

5.  Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS).

Authors:  Ancha Baranova; Thuy Phuong Tran; Arian Afendy; Lei Wang; Amirhossein Shamsaddini; Rohini Mehta; Vikas Chandhoke; Aybike Birerdinc; Zobair M Younossi
Journal:  J Transl Med       Date:  2013-05-31       Impact factor: 5.531

6.  Lactoferrin dampens high-fructose corn syrup-induced hepatic manifestations of the metabolic syndrome in a murine model.

Authors:  Yi-Chieh Li; Chang-Chi Hsieh
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.